Brief: Sedana Medical Funds A Large Study With Isoflurane

Sedana Medical AB (publ)

04/12/2019 07:12

Dec 4 (Reuters) - Sedana Medical AB (publ)  SEDANA.ST :
    * TODAY ANNOUNCED THAT COMPANY IS FUNDING A LARGE FRENCH
MULTICENTER STUDY WITH ISOFLURANE - SUBSTANCE IN COMPANY'S DRUG
CANDIDATE ISOCONDA - DELIVERED BY COMPANY'S MEDICAL DEVICE
ANACONDA
    * A POSITIVE RESULT WOULD SIGNIFICANTLY STRENGTHEN COMPANY'S
CLINICAL BASE FOR REGULATORY AND COMMERCIAL EXPANSION
    * STUDY WILL BEGIN EARLY 2020 AND IS EXPECTED TO BE
FINALIZED IN
EARLY 2023 AFTER 24 MONTHS OF INCLUSION AND A TWELVE-MONTH
COGNITIVE FOLLOW UP
    * AIM IS MAINLY TO SHOW A REDUCED INCIDENCE OF DELIRIUM IN
MECHANICALLY VENTILATED INTENSIVE CARE PATIENTS COMPARED TO
INTRAVENOUS SEDATION WITH PROPOFOL
    * PRIMARY ENDPOINT OF STUDY IS INCIDENCE OF DELIRIUM AFTER
SEDATION WITH ISOFLURANE VIA ANACONDA, COMPARED WITH CURRENT
INTRAVENOUS STANDARD THERAPY PROPOFOL
    * SECONDARY ENDPOINTS INCLUDE DELIRIUM-FREE DAYS AFTER
SEDATION,
VENTILATOR-FREE DAYS, ICU-FREE DAYS, 28-DAY MORTALITY, THREE-
AND TWELVE MONTHS COGNITIVE OUTCOMES, HEMODYNAMIC EFFECTS OF
SEDATION, ORGAN SAFETY ASSESSMENT, QUALITY OF LIFE AND A
HEALTH-ECONOMICAL EVALUATION

Source text for Eikon:  ID:nWkr3s0JKb 
Further company coverage:  SEDANA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))